PK/TK Analysis of Multiple Dosing

2015 ◽  
pp. 446-467
Keyword(s):  
Multiple Dosing

Plasma and brain pharmacokinetics of mianserin after single and multiple dosing in mice

1987 ◽  
Vol 11 (1) ◽  
pp. 23-33 ◽  
Author(s):  
Alfredo Carlo Altamura ◽  
Fedele De Novellis ◽  
Massimo C. Mauri ◽  
Roberto Gomeni
Keyword(s):  
Multiple Dosing

scholarly journals Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.

1985 ◽  
Vol 20 (6) ◽  
pp. 611-618 ◽  
Author(s):  
PN Shaw ◽  
JB Houston ◽  
M. Rowland ◽  
K. Hopkins ◽  
JF Thiercelin ◽  
...  
Keyword(s):  
Metabolite Kinetics ◽  
Multiple Dosing ◽  
Healthy Human ◽  
Human Volunteers

P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing

2005 ◽  
Vol 56 (3) ◽  
pp. 248-254 ◽  
Author(s):  
Daniel L. Gustafson ◽  
Michael E. Long ◽  
Erica L. Bradshaw ◽  
Andrea L. Merz ◽  
Patrick J. Kerzic
Keyword(s):  
Tissue Distribution ◽  
Multiple Dosing

Development of Floating Multiple Unit Minitablets of Bosentan using QbD: Characterisation and Pharmacokinetic Study

2021 ◽  
Vol 11 ◽  
Author(s):  
Santosh Kumar Panda ◽  
Manoranjan Sahu ◽  
Kahnu Charan Panigrahi ◽  
Chinam Niranjan Patra ◽  
Goutam Kumar Jena
Keyword(s):  
Quality By Design ◽  
Critical Factor ◽  
Taguchi Design ◽  
Multiple Dosing ◽  
Release Formulation ◽  
Effect Analysis ◽  
Box Behnken Design ◽  
Multiple Unit ◽  
Quality By Design Approach ◽  
State Concentration

Background: In order to achieve steady state concentration multiple dosing is required for bosentan. Hence formulating bosentan controlled release formulation could be an approach to solve this issue. Objective: The objective is to develop floating multiple unit minitablets of bosentan using Quality by design approach. Methods: : Failure mode effect analysis (FMEA) and taguchi design employed in order to screen highly critical factor. Box-Behnken design (BBD) was adopted for the process of optimization. Results: : Amount of gelucire 39/01, HPMC K15 M and sodium bicarbonate were screened as significant factor using Taguchi design. The Box-Behnken design results the optimised formulation showing floating lag time within 3 min, floating time of nearly 15 h, time to release 50% of drug of 3.6 h and time to release 90% of drug of 11h and better bioavailability compared to pure drug. Conclusion: : It can be concluded that floating multiple unit minitablet can be used as an encouraging approach for sustaining the drug release of bosentan.

scholarly journals Multiple Oral Dosing Pharmacokinetics of Standardized Extract of Centella asiatica ECa 233 and Its Inductive Effect on Efflux Transporters in Rats

2017 ◽  
Vol 4 (02) ◽  
pp. e66-e73 ◽  
Author(s):  
Tosapol Anukunwithaya ◽  
Mayuree Tantisira ◽  
Tsutomu Shimada ◽  
Yoshimichi Sai ◽  
Phisit Khemawoot
Keyword(s):  
Inductive Effect ◽  
Area Under The Curve ◽  
Centella Asiatica ◽  
Pharmacokinetic Data ◽  
Maximum Plasma ◽  
Asiatic Acid ◽  
Multiple Dosing ◽  
Oral Dosing ◽  
Blood Biochemical ◽  
Triterpenoid Glycosides

AbstractECa 233 is a standardized extract of Centella asiatica, characterized as a white powder containing triterpenoid glycosides not less than 80% with a ratio of madecassoside to asiaticoside of 1.5±0.5:1. Although pharmacological and toxicological profiles of ECa 233 have been successively reported, the pharmacokinetic data needed for further therapeutic development are not fully elucidated. This study aimed to investigate the pharmacokinetics of multiple oral dosing of ECa 233 at 100 mg/kg/day for 7 days in rats. Plasma, tissues, urine, and feces were collected from 0 to 24 h after dosing on days 1 and 7. The concentrations of asiaticoside, madecassoside, asiatic acid, and madecassic acid were simultaneously analyzed by liquid chromatography-tandem mass spectrometry. No significant change was observed in physical and blood biochemical parameters of the animals treated with ECa 233 for 7 days. The maximum plasma concentration and area under the curve at day 7 of madecassoside and asiaticoside decreased by 70–80% from day 1. However, both triterpenoid glycosides were extensively distributed and accumulated, resulting in significantly higher concentrations at pharmacologically relevant organs. Madecasssic acid and asiatic acid are major metabolites mainly found in and excreted via feces. Moreover, multiple dosing of ECa 233 increased mRNA expression of Abcb1a and Abcc2 in the small intestine by approximately 2- to 3-fold. This is the first study to identify an inductive effect of a standardized extract of C. asiatica after multiple oral dosing in rats. Potential drug-herb interactions when ECa 233 is coadministered with Abcb1a and Abcc2 substrates calls for further investigations.

Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing

1994 ◽  
Vol 55 (1) ◽  
pp. 21-27 ◽  
Author(s):  
Parnian Zia-Amirhosseini ◽  
Joseph C Ojingwa ◽  
Hildegard Spahn-Langguth ◽  
Antony F McDonagh ◽  
Leslie Z Benet
Keyword(s):  
Covalent Binding ◽  
Multiple Dosing
Sign in / Sign up

Export Citation Format

Share Document